Discovery

Seoul team extends prime editing to large-scale DNA replacement

Seoul team extends prime editing to large-scale DNA replacement

Researchers at Seoul National University College of Medicine have developed a prime editing-based system capable of replacing genomic sequences with DNA payloads up to 6.5 kilobases in size and excising genomic regions spanning up to one megabase without introducing double-strand breaks (DSBs), according to a study published August 28 in Nature Biotechnology. The work, led by corresponding author Sangsu Bae, addresses a persistent limitation of precision genome editing: efficiently replacing large genomic segments without relying on DSB-mediated repair.

Standard prime editing, which uses a Cas9 nickase fused to a reverse transcriptase to write short sequences into the genome, is well suited to point mutations and small insertions but becomes less efficient as payload size increases. Homology-directed repair (HDR)-based approaches can accommodate larger inserts but require DSBs, carry risks including unwanted indels and chromosomal rearrangements, and are generally less effective in non-dividing cells. The new system, which the authors call prime assembly (PA), extends the prime editing architecture to kilobase-scale gene replacement.

Mechanism

PA generates complementary single-stranded 3′ flaps on both the genomic target and donor DNA using prime editing machinery directed by engineered prime editing guide RNAs (pegRNAs). These genomic and donor flaps anneal to one another in a Gibson assembly-like process, followed by strand invasion and DNA synthesis.

Mechanistic experiments identified RAD51-mediated strand invasion as an important dependency: pharmacological RAD51 inhibition reduced PA efficiency in a dose-dependent manner. By contrast, inhibition of DNA-PKcs-mediated canonical non-homologous end joining modestly reduced the efficiency of some PA configurations, suggesting that PA does not simply operate through conventional DSB-dependent integration pathways.

Three configurations were developed: single-flap PA (SF-PA), which uses a homology arm; single-flap PA with an additional nicking guide RNA (SFn-PA), designed to improve strand invasion; and dual-flap PA (DF-PA), which uses two pairs of complementary flaps to bracket a genomic region, enabling simultaneous excision and donor insertion without conventional homology arms.

Key findings

The researchers demonstrated PA activity across six cell lines — HEK293T, HEK293, HeLa, K562, HuH7, and Hepa-1c1c7 — and at multiple endogenous loci. PA accepted circular plasmid and linear double-stranded DNA donors ranging from 1.0 to 6.5 kb.

The system achieved replacement efficiency of up to 57.8% at endogenous loci. Long-read sequencing showed precise donor incorporation without major alterations in 93.7%, 84.3%, and 77.5% of donor-integrated reads for SF-PA, SFn-PA, and DF-PA, respectively.

The authors also conducted a genome-wide off-target integration analysis using a modified GUIDE-seq approach. No notable off-target integration event accounting for more than 0.06% of total reads was detected for any of the three PA formats.

DF-PA was additionally able to excise genomic regions spanning 100 kb and approximately 1 Mb while inserting a 2.9-kb donor sequence.

In disease-relevant models, PA replaced exon 1 of HTT containing expanded CAG repeats with a synthesized sequence containing ten repeats in HEK293T cells. The researchers also modeled correction strategies for pathogenic variants in GSDME and SLC39A14 and integrated an F9 cassette at the ALB locus in HuH7 hepatocyte cells as a model for hemophilia B gene therapy.

In primary human T cells, PA-mediated insertion of a CD19 CAR cassette generated CAR-positive populations of 8.3% with SF-PA, 19.1% with SFn-PA, and 28.1% with DF-PA. Edited cells expanded approximately 20-fold over seven days and demonstrated antigen-dependent killing of CD19-positive Raji cells in vitro. PA-engineered CAR-T cells also suppressed tumor growth in a Raji xenograft mouse model.

In vivo delivery using hydrodynamic tail-vein injection in C57BL/6J mice produced an average integration efficiency of 4.3% among GFP-positive hepatocytes.

The AllSci BriefSystematic R&D and deal news. Daily.

Competitive context

PA joins a rapidly expanding group of approaches designed to extend prime editing and related DSB-free technologies to larger genomic changes.

A closely related method, donor-complementary prime editing (DoPE), was published in Nature Biotechnology on the same day as the Seoul group's paper. DoPE combines complementary 3′-overhang DNA donors with engineered prime editing guides and demonstrated precise insertion of DNA sequences as large as 12.5 kb.

Confusingly, a separate technology also called prime assembly was reported by researchers led by Wen Xue in Nature in April 2026. That system uses twin prime editing-generated genomic flaps together with complementary linear double-stranded DNA donors and demonstrated insertions ranging from 0.1 kb to 11 kb, including 0.8-kb integration at efficiencies of up to approximately 40%.

Sangamo Therapeutics is pursuing a mechanistically distinct large-fragment integration approach through its Modular Integrase (MINT) platform, which retargets the Bxb1 serine integrase to endogenous genomic loci without first installing a synthetic landing pad.

At the clinical frontier for DSB-free templated genome rewriting, Tessera Therapeutics' TSRA-196, jointly developed with Regeneron for alpha-1 antitrypsin deficiency (AATD), received US FDA IND clearance in January 2026 and Fast Track and Orphan Drug designations the following month. TSRA-196 uses an RNA-delivered Cas nickase–reverse transcriptase system to rewrite the pathogenic PiZ variant in SERPINA1 and is now being evaluated in a Phase I/II study. Unlike PA, however, TSRA-196 is designed for a small sequence correction rather than kilobase-scale genomic replacement.

The clinical benchmark for conventional prime editing is Prime Medicine's PM359, an ex vivo prime-edited autologous CD34+ hematopoietic stem cell therapy for p47phox-deficient chronic granulomatous disease (CGD). In an ongoing Phase I/II trial, two patients had received PM359 in results published online in the New England Journal of Medicine in December 2025. NADPH oxidase activity emerged within one month and was maintained through six months in the first patient and four months in the second at the latest follow-up reported in the paper. PM359 corrects a two-base deletion rather than replacing a large genomic segment, but provides clinical proof of concept for prime editing in human cells.

Translational stage and limitations

The PA system remains preclinical, and no clinical development program has been announced for the technology.

Although the authors conducted genome-wide screening for unintended donor integration, broader characterization of editing specificity, genotoxicity, and genomic integrity will be needed before therapeutic application. DF-PA in particular showed lower proportions of fully precise donor integrations than SF-PA and SFn-PA in long-read sequencing, with some integration events involving damaged flap sequences or partial donor integration.

Delivery also remains a major translational challenge. The in vivo experiment relied on hydrodynamic tail-vein injection, an experimental method used extensively in mice but not directly applicable as a therapeutic delivery route in humans. Editing was measured at 4.3% among GFP-positive hepatocytes rather than across the total liver-cell population.

The disease-focused experiments are proof-of-concept models rather than demonstrations of therapeutic correction in animals or patients. Further work will need to determine whether PA can retain its efficiency and precision in clinically relevant primary cells and tissues while supporting practical delivery of both the prime editing machinery and large DNA donor templates.


Spot something wrong? Report an issue with this article